Northern Trust Corp grew its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 11.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 296,467 shares of the company's stock after buying an additional 30,111 shares during the period. Northern Trust Corp owned 0.73% of Keros Therapeutics worth $4,693,000 at the end of the most recent reporting period.
Other large investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. raised its stake in Keros Therapeutics by 585.9% during the 4th quarter. JPMorgan Chase & Co. now owns 213,431 shares of the company's stock valued at $3,379,000 after purchasing an additional 182,314 shares during the period. SG Americas Securities LLC bought a new stake in Keros Therapeutics during the 4th quarter valued at approximately $388,000. Barclays PLC raised its stake in Keros Therapeutics by 140.1% during the 3rd quarter. Barclays PLC now owns 60,014 shares of the company's stock valued at $3,484,000 after purchasing an additional 35,022 shares during the period. Norges Bank bought a new stake in Keros Therapeutics during the 4th quarter valued at approximately $1,027,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in Keros Therapeutics during the 4th quarter valued at approximately $461,000. 71.56% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on KROS. Wedbush reissued a "neutral" rating and set a $15.00 target price on shares of Keros Therapeutics in a research note on Tuesday, April 1st. Scotiabank decreased their target price on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a research note on Monday, May 12th. Truist Financial decreased their target price on Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating on the stock in a research note on Wednesday, April 9th. HC Wainwright decreased their target price on Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Finally, Wells Fargo & Company reduced their price objective on Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, February 27th. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, Keros Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $37.00.
Check Out Our Latest Analysis on KROS
Keros Therapeutics Trading Up 2.9%
Shares of NASDAQ KROS traded up $0.41 during trading hours on Friday, hitting $14.57. 581,064 shares of the company traded hands, compared to its average volume of 840,497. The stock has a market capitalization of $591.76 million, a price-to-earnings ratio of -2.80 and a beta of 1.32. The company's 50 day moving average price is $12.70 and its 200 day moving average price is $21.54. Keros Therapeutics, Inc. has a 12 month low of $9.12 and a 12 month high of $72.37.
Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $3.63. The firm had revenue of $211.25 million for the quarter, compared to the consensus estimate of $84.62 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. During the same quarter in the previous year, the company posted ($1.21) EPS. Equities analysts anticipate that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.
Insider Activity
In related news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of the business's stock in a transaction dated Wednesday, April 9th. The shares were purchased at an average price of $10.13 per share, with a total value of $9,464,033.54. Following the transaction, the insider now owns 4,392,737 shares in the company, valued at $44,498,425.81. This trade represents a 27.01% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 20.60% of the company's stock.
About Keros Therapeutics
(
Free Report)
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
See Also
Before you consider Keros Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Keros Therapeutics wasn't on the list.
While Keros Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
